血清和慢性阻塞性肺疾病患者呼吸道样本中免疫球蛋白同种型水平：系统评价和荟萃分析方案。

Levels of immunoglobulin isotypes in serum and respiratory samples of patients with chronic obstructive pulmonary disease: protocol for a systematic review and meta-analysis.

机构信息

Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.

Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada.

出版信息

BMJ Open. 2023 Feb 9;13(2):e064307. doi: 10.1136/bmjopen-2022-064307.

DOI:10.1136/bmjopen-2022-064307

PMID:36759034

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9923280/

Abstract

INTRODUCTION

Chronic obstructive pulmonary disease (COPD) is an inflammatory respiratory disorder characterised by the progressive worsening of lung function. Acute exacerbation of COPD (AECOPD) is a leading contributor to patient morbidity, mortality and hospitalisations. The clinical significance of immunoglobulin (Ig) levels in COPD patients is not well established and is in need of further investigation.

METHODS AND ANALYSIS

We will conduct a systematic review to describe levels of different Ig isotypes (IgG, IgA and IgM) in various samples (serum, sputum and bronchoalveolar lavage) of patients with COPD. IgE levels in COPD patients have been researched and reviewed extensively and hence will be excluded from this review. IgD levels will also be excluded from the review as there is a paucity of data on IgD levels in COPD patients. The primary outcome of interest in this systematic review is assessing Ig isotype levels in patients with COPD. Secondary outcomes that will be assessed include the differences between Ig isotype levels in COPD patients compared with healthy controls, as well as the relationships between Ig isotype levels and key clinical variables, including COPD severity, incidence of AECOPD and AECOPD severity. Embase and Ovid MEDLINE will be used to search for non-randomised studies published from 1946 to October 2022 that report our prespecified primary and secondary outcomes. As per the Preferred Reporting Items for Systematic Reviews and Meta-Analyses protocol, retrieved studies will undergo a two-phase screening process conducted by two independent reviewers. Prespecified primary and secondary outcomes will be extracted from eligible studies, and descriptive statistics will be used to analyse extracted outcomes. The risk of bias will be assessed using the Risk Of Bias In Non-randomised Studies - of Interventions (ROBINS-I) tool.

ETHICS AND DISSEMINATION

Ethics approval is not required as this is a protocol for a systematic review and meta-analysis. Findings will be disseminated through peer-reviewed publications and other formats including conference presentations.

PROSPERO REGISTRATION NUMBER

CRD42020192220.

摘要

简介

慢性阻塞性肺疾病（COPD）是一种以肺功能进行性恶化为特征的炎症性呼吸系统疾病。COPD 急性加重（AECOPD）是导致患者发病率、死亡率和住院率升高的主要原因。免疫球蛋白（Ig）水平在 COPD 患者中的临床意义尚未得到充分证实，需要进一步研究。

方法和分析

我们将进行系统评价，描述 COPD 患者不同免疫球蛋白同种型（IgG、IgA 和 IgM）在各种样本（血清、痰液和支气管肺泡灌洗液）中的水平。IgE 水平在 COPD 患者中的研究和综述已经很广泛，因此将不包括在本次综述中。IgD 水平也将不包括在综述中，因为 COPD 患者的 IgD 水平数据很少。本次系统评价的主要研究结果是评估 COPD 患者的 Ig 同种型水平。评估的次要结果包括 COPD 患者与健康对照组之间 Ig 同种型水平的差异，以及 Ig 同种型水平与关键临床变量之间的关系，包括 COPD 严重程度、AECOPD 发生率和 AECOPD 严重程度。将使用 Embase 和 Ovid MEDLINE 检索 1946 年至 2022 年 10 月发表的非随机研究，报告我们预先指定的主要和次要结局。根据系统评价和荟萃分析的首选报告项目协议，检索到的研究将经过两名独立评审员进行的两阶段筛选过程。将从合格研究中提取预先指定的主要和次要结局，并使用描述性统计分析提取的结局。使用非随机干预的风险偏倚评估工具（ROBINS-I）评估偏倚风险。